← Leaderboards
John C Grecula
Ohio State University
$685,876
Attributed
$685,876
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $337.5K · FY2008–09$500K$375K$250K$125K$0
'08
'09
Funding mix
By agency
NIH$685,876 · 3
By mechanism
R21$675,000 · 1
M01$10,876 · 2
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Matthew D Ringel$21,305,885
- Nicholas C Denko$10,501,039
- Lawrence S Kirschner$10,043,463
- Albert De La Chapelle$15,372,498
- Zihai Li$25,199,729
Others in their field
Top investigators on “Hypoxia”
- James B Edson · Woods Hole Oceanographic Institution$110,367,520
- Albert J Plueddemann · Woods Hole Oceanographic Institution$110,367,520
- David Heimbrook · Leidos Biomedical Research, Inc.$41,862,534
- Nanduri R Prabhakar · Case Western Reserve University$32,967,177
- Zaver M Bhujwalla · Johns Hopkins University$30,055,665
- Donna M. Ferriero · University Of California, San Francisco$27,259,560
Research focus
HypoxiaAlgorithmsGadoliniumHuman Therapy EvaluationCancer PatientCancer TherapyBaseFutureHuman SubjectCharacteristicsChemotherapyClinical ResearchClinical Trial Phase ICluster AnalysisCancer TypeComplementCancer EtiologyDisease-Free SurvivalCessation Of LifeCancer ImagingEffectivenessExcisionFailure (Biologic Function)Image
Grant awards (4)
MR-predictive-assay in pre-operative lung cancer therapy: response/resectability$337,500
R21 · FY2009 · CA · contact PI
MR-predictive-assay in pre-operative lung cancer therapy: response/resectability$337,500
R21 · FY2008 · CA · contact PI
Phase I Trial of Gadolinium Texaphyrin (PCI-02120)$7,854
M01 · FY2004 · RR
Phase I Study of Induction Carboplatin/Paclitaxel Chemotherapy$3,022
M01 · FY2004 · RR